Inflammasome biology, molecular pathology and therapeutic implications
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
&NA; Inflammasomes are intracellular multiprotein signaling complexes, mainly present in myeloid cells. They commonly assemble around a cytoplasmic receptor of the nucleotide‐binding leucine‐rich repeat containing receptor (NLR) family, although other cytoplasmic receptors like pyrin have been shown to form inflammasomes. The nucleation of the multiprotein scaffolding platform occurs upon detection of a microbial, a danger or a homeostasis pattern by the receptor that will, most commonly, associate with the adaptor protein ASC (apoptosis‐associated speck‐like protein containing a CARD) through homotypic domain interactions resulting in recruitment of procaspase‐1. This will lead to the autoproteolytic activation of caspase‐1, which regulates the secretion of proinflammatory IL1&bgr; and IL18 cytokines and pyroptosis, a caspase‐1‐mediated form of cell death. Pyroptosis occurs through cleavage of Gasdermin D, a membrane pore forming protein. Recently, non‐canonical inflammasomes have been described, which directly sense intracellular pathogens through caspase‐4 and ‐5 in humans, leading to pyroptosis. Inflammasomes are important in host defense; however, a deregulated activity is associated with a number of inflammatory, immune and metabolic disorders. Furthermore, mutations in inflammasome receptor coding genes are causal for an increasing number of rare autoinflammatory diseases. Biotherapies targeting the products of inflammasome activation as well as molecules that directly or indirectly inhibit inflammasome nucleation and activation are promising therapeutic areas. This review discusses recent advances in inflammasome biology, the molecular pathology of several inflammasomes, and current therapeutic approaches in autoinflammatory diseases and in selected common multifactorial inflammasome‐mediated disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 3×
“Similarly, cholesterol crystals injected intraperitoneally induced an acute inflammation that was impaired in mice deficient in inflammasome components (Duewell et al., 2010).”
BackgroundResultCaspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Kayagaki, N., Stowe, I. B., Lee, B. L., O’Rourke, K., Anderson, K., Warming, S., Cuellar, T., Haley, B., Roose-Girma, M., Phung, Q. T., et al. (2015) · Nature · doi:10.1038/nature15541 · Cited by 3,686 · cited 1×
“Pyroptosis induction was recently shown to be linked to gasdermin-D (GSDMD), a protein with membrane poreforming activity (Kayagaki et al., 2015; Liu et al., 2016).”
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“Once generated, the N-terminal part of GSDMD targets the cytoplasmic face of the plasma membrane, due to its affinity for phospholipids like phosphorylated phosphatidylinositols and cardiolipin (Liu et al., 2016).”
BackgroundCryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Cited by
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1413-8 · Cited by 1,269
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258
Liu, W., Liu, A., Li, X., Sun, Z., Sun, Z., Liu, Y., Wang, G., Huang, D., Xiong, H., Yu, S., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.06.012 · Cited by 107
Jafarzadeh, A., & Nemati, M. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.09.003 · Cited by 84
Metadata
- Authors
- Awad, F., Assrawi, E., Louvrier, C., Jumeau, C., Georgin-Lavialle, S., Grateau, G., Amselem, S., Giurgea, I., & Karabina, S.-A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 187
- Pages
- 133-149
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2791974746
- Cited by
- 134
- References
- 62
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammasome biology, molecular pathology and therapeutic implications. https://app.cochat.ai/papers/10.1016/j.pharmthera.2018.02.011
- The paper
- Awad, F., Assrawi, E., Louvrier, C., Jumeau, C., Georgin-Lavialle, S., Grateau, G., Amselem, S., Giurgea, I., & Karabina, S.-A. (2018). Inflammasome biology, molecular pathology and therapeutic implications. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.02.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.